Sinovac Biotech (SVA) 4.90 $SVA
Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5mrz3/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" report to their offering. Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" provides data on the Hand, Foot And Mouth Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hand, Foot And Mouth Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hand, Foot And Mouth Disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Hand, Foot And Mouth Disease Therapeutics Clinical Trials - Sinovac Biotech Co., Ltd. - Jiangxi Qingfeng Pharmaceutical Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Inviragen, Inc. (Inactive) Clinical Trial Overview of Top Institutes / Government - Jiangsu Provincial Center for Disease Control and Prevention - China Academy of Chinese Medical Sciences - Chinese Academy of Medical Sciences and Peking Union Medical College - Oxford University Clinical Research Unit - Capital Medical University - Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing University of Chinese Medicine - Zhengzhou University - Tianjin University of Traditional Chinese Medicine For more information visit http://www.researchandmarkets.com/research/k5...d_foot_and
SVA: 4.90 (+0.02)
Enterovirus Infections - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/4lm9wd/enterovirus) has announced the addition of the "Enterovirus Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Enterovirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterovirus Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterovirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterovirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Medigen Biotechnology Corporation - Sinovac Biotech Ltd. - Beijing Minhai Biotechnology Co., Ltd - Shanghai Zerun Biotechnology Co., Ltd. - Sentinext Therapeutics Sdn Bhd For more information visit http://www.researchandmarkets.com/research/4l...nterovirus
SVA: 4.90 (+0.02)
Rabies - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ck5b5/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rabies - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology - Celltrion - Crucell - CureVac - Humabs BioMed - Kaketsuken - Kamada - Medicago - Molecular Targeting Technologies - NanoViricides - Novavax - PaxVax - Sanofi Pasteur - Serum Institute of India Limited - Sinovac Biotech - Trellis Bioscience - VBI Vaccines - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/7c...s_pipeline
VBIV: 3.48 (-0.03), SVA: 4.90 (+0.02)
Diphtheria - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/7gbxhb/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology - Biological E - Daiichi Sankyo Company - GlaxoSmithKline - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/7gbxhb/diphtheria
GSK: 42.42 (-0.93), SVA: 4.90 (+0.02), NVS: 93.52 (-0.82)
Simavita Limited: Results From 2014 Annual General and Special Meeting
Marketwired - Wed Dec 03, 12:02PM CST
Simavita Limited ("Simavita" or the "Company"
(ASX: SVA)(TSX VENTURE: SV) advises that the 2014 Annual General and Special Meeting of shareholders was held at 10.00 am today (Sydney time) at the offices of Dibbs Barker, Level 8, 123 Pitt Street, Sydney, New South Wales, Australia.
SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 15.94 (+0.74), JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ASMB: 7.35 (-0.09), GSK: 42.42 (-0.93), SVA: 4.90 (+0.02)
Simavita Releases Unaudited Financial Results for the Three Months Ended September 30, 2014
Marketwired - Fri Nov 28, 12:24PM CST
Simavita Limited ("Simavita" or the "Company" (TSX VENTURE: SV)(ASX: SVA) announced today its financial results for the first quarter ended September 30, 2014, reported in Australian dollars and in accordance with International Financial Reporting Standards ("IFRS" . The Company's results are presented in comparison to the three months ended September 30, 2013, which were also prepared in accordance with IFRS.
SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
China Human Vaccine Industry Forecasts and Opportunities, 2017
M2 - Wed Nov 26, 6:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/4xrghp/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2014-2017" report to their offering. Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China's human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run. Affected by China's economic level, national vaccine prevention policies and people's awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine IPV for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine OPV for the third and fourth vaccinations. Key Topics Covered: 1. Overview of Vaccine Industry 2. China Human Vaccine Industry & Market 3. Human Vaccine Market Segments in China 4. China's Import and Export of Vaccines 5. Major Vaccine Manufacturers in China Companies Mentioned - Beijing Tiantan Biological Products Co., Ltd - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd - Dalian Hissen Bio-Pharm Co., Ltd - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd - Sinovac Biotech Ltd. - Walvax Biotechnology Co., Ltd - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/4x...hina_human
SVA: 4.90 (+0.02)
Sinovac's (SVA) CEO Weidong Yin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 17, 12:29PM CST
SVA: 4.90 (+0.02)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 15.94 (+0.74), BAX: 71.77 (-1.34), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), SVA: 4.90 (+0.02)
Sinovac Biotech beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:55PM CST
SVA: 4.90 (+0.02)
Sinovac posts 3Q profit
Automated Insights - Fri Nov 14, 3:40PM CST
BEIJING (AP) _ Sinovac Biotech Ltd. (SVA) on Friday reported net income of $89,000, or roughly breakeven on a per-share basis, in its third quarter.
SVA: 4.90 (+0.02)
Sinovac Reports Unaudited Third Quarter Financial Results
PR Newswire - Fri Nov 14, 3:30PM CST
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2014.
SVA: 4.90 (+0.02)
Simavita Expands Board of Directors by Appointing Craig Holland and Adds Appointment to Upcoming Shareholder Meeting Agenda
Marketwired - Fri Nov 14, 7:32AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to advise the appointment, effective immediately, of Mr. Craig Holland as an independent, non-executive Director of the Company. Mr. Holland will also be appointed as Chairman of the Company's Audit and Risk Committee.
SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 5.76 (-0.17), KMDA: 3.51 (-0.02), VBIV: 3.48 (-0.03), NNVC: 2.80 (-0.07), SVA: 4.90 (+0.02)
Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results
PR Newswire - Wed Nov 05, 3:00AM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter, ended September 30, 2014, after market close on Friday, November 14, 2014 ET. The Company will host a conference call prior to the market opening on Monday, November 17, 2014, at 8:00 a.m. ET (Monday, November 17, 2014 at 9:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 4.90 (+0.02)
Simavita Limited: Pilots Drive Further SIM(TM) Growth in Australia, US and Europe
Marketwired - Mon Nov 03, 4:02PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) -
SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5mrz3/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" report to their offering. Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" provides data on the Hand, Foot And Mouth Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hand, Foot And Mouth Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hand, Foot And Mouth Disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Hand, Foot And Mouth Disease Therapeutics Clinical Trials - Sinovac Biotech Co., Ltd. - Jiangxi Qingfeng Pharmaceutical Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Inviragen, Inc. (Inactive) Clinical Trial Overview of Top Institutes / Government - Jiangsu Provincial Center for Disease Control and Prevention - China Academy of Chinese Medical Sciences - Chinese Academy of Medical Sciences and Peking Union Medical College - Oxford University Clinical Research Unit - Capital Medical University - Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing University of Chinese Medicine - Zhengzhou University - Tianjin University of Traditional Chinese Medicine For more information visit http://www.researchandmarkets.com/research/k5...d_foot_and
SVA: 4.90 (+0.02)
Enterovirus Infections - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/4lm9wd/enterovirus) has announced the addition of the "Enterovirus Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Enterovirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterovirus Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterovirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterovirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Medigen Biotechnology Corporation - Sinovac Biotech Ltd. - Beijing Minhai Biotechnology Co., Ltd - Shanghai Zerun Biotechnology Co., Ltd. - Sentinext Therapeutics Sdn Bhd For more information visit http://www.researchandmarkets.com/research/4l...nterovirus
SVA: 4.90 (+0.02)
Rabies - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ck5b5/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rabies - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology - Celltrion - Crucell - CureVac - Humabs BioMed - Kaketsuken - Kamada - Medicago - Molecular Targeting Technologies - NanoViricides - Novavax - PaxVax - Sanofi Pasteur - Serum Institute of India Limited - Sinovac Biotech - Trellis Bioscience - VBI Vaccines - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/7c...s_pipeline
VBIV: 3.48 (-0.03), SVA: 4.90 (+0.02)
Diphtheria - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/7gbxhb/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology - Biological E - Daiichi Sankyo Company - GlaxoSmithKline - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/7gbxhb/diphtheria
GSK: 42.42 (-0.93), SVA: 4.90 (+0.02), NVS: 93.52 (-0.82)
Simavita Limited: Results From 2014 Annual General and Special Meeting
Marketwired - Wed Dec 03, 12:02PM CST
Simavita Limited ("Simavita" or the "Company"
(ASX: SVA)(TSX VENTURE: SV) advises that the 2014 Annual General and Special Meeting of shareholders was held at 10.00 am today (Sydney time) at the offices of Dibbs Barker, Level 8, 123 Pitt Street, Sydney, New South Wales, Australia. SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 15.94 (+0.74), JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ASMB: 7.35 (-0.09), GSK: 42.42 (-0.93), SVA: 4.90 (+0.02)
Simavita Releases Unaudited Financial Results for the Three Months Ended September 30, 2014
Marketwired - Fri Nov 28, 12:24PM CST
Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE: SV)(ASX: SVA) announced today its financial results for the first quarter ended September 30, 2014, reported in Australian dollars and in accordance with International Financial Reporting Standards ("IFRS" . The Company's results are presented in comparison to the three months ended September 30, 2013, which were also prepared in accordance with IFRS. SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
China Human Vaccine Industry Forecasts and Opportunities, 2017
M2 - Wed Nov 26, 6:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/4xrghp/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2014-2017" report to their offering. Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China's human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run. Affected by China's economic level, national vaccine prevention policies and people's awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine IPV for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine OPV for the third and fourth vaccinations. Key Topics Covered: 1. Overview of Vaccine Industry 2. China Human Vaccine Industry & Market 3. Human Vaccine Market Segments in China 4. China's Import and Export of Vaccines 5. Major Vaccine Manufacturers in China Companies Mentioned - Beijing Tiantan Biological Products Co., Ltd - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd - Dalian Hissen Bio-Pharm Co., Ltd - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd - Sinovac Biotech Ltd. - Walvax Biotechnology Co., Ltd - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/4x...hina_human
SVA: 4.90 (+0.02)
Sinovac's (SVA) CEO Weidong Yin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 17, 12:29PM CST
SVA: 4.90 (+0.02)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 15.94 (+0.74), BAX: 71.77 (-1.34), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), SVA: 4.90 (+0.02)
Sinovac Biotech beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:55PM CST
SVA: 4.90 (+0.02)
Sinovac posts 3Q profit
Automated Insights - Fri Nov 14, 3:40PM CST
BEIJING (AP) _ Sinovac Biotech Ltd. (SVA) on Friday reported net income of $89,000, or roughly breakeven on a per-share basis, in its third quarter.
SVA: 4.90 (+0.02)
Sinovac Reports Unaudited Third Quarter Financial Results
PR Newswire - Fri Nov 14, 3:30PM CST
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2014.
SVA: 4.90 (+0.02)
Simavita Expands Board of Directors by Appointing Craig Holland and Adds Appointment to Upcoming Shareholder Meeting Agenda
Marketwired - Fri Nov 14, 7:32AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to advise the appointment, effective immediately, of Mr. Craig Holland as an independent, non-executive Director of the Company. Mr. Holland will also be appointed as Chairman of the Company's Audit and Risk Committee. SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 5.76 (-0.17), KMDA: 3.51 (-0.02), VBIV: 3.48 (-0.03), NNVC: 2.80 (-0.07), SVA: 4.90 (+0.02)
Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results
PR Newswire - Wed Nov 05, 3:00AM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter, ended September 30, 2014, after market close on Friday, November 14, 2014 ET. The Company will host a conference call prior to the market opening on Monday, November 17, 2014, at 8:00 a.m. ET (Monday, November 17, 2014 at 9:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 4.90 (+0.02)
Simavita Limited: Pilots Drive Further SIM(TM) Growth in Australia, US and Europe
Marketwired - Mon Nov 03, 4:02PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) -
SV.VN: 0.500 (-0.050), SVA: 4.90 (+0.02)
